The nuclear export protein XPO1—from biology to targeted therapy

AS Azmi, MH Uddin, RM Mohammad - Nature reviews Clinical oncology, 2021 - nature.com
Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

XPO1-dependent nuclear export as a target for cancer therapy

NG Azizian, Y Li - Journal of hematology & oncology, 2020 - Springer
Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …

[HTML][HTML] Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE …

T Martin, SZ Usmani, JG Berdeja, M Agha… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma …

JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak… - The Lancet, 2021 - thelancet.com
Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

[HTML][HTML] Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma

N Raje, J Berdeja, YI Lin, D Siegel… - … England Journal of …, 2019 - Mass Medical Soc
Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

[HTML][HTML] Oral selinexor–dexamethasone for triple-class refractory multiple myeloma

A Chari, DT Vogl, M Gavriatopoulou… - … England Journal of …, 2019 - Mass Medical Soc
Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …

The multiple myelomas—current concepts in cytogenetic classification and therapy

SK Kumar, SV Rajkumar - Nature reviews Clinical oncology, 2018 - nature.com
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

The intersection of COVID-19 and cancer: signaling pathways and treatment implications

Z Zong, Y Wei, J Ren, L Zhang, F Zhou - Molecular cancer, 2021 - Springer
The outbreak of the novel coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a serious public health …

FDA-approved drugs for hematological malignancies—the last decade review

A Sochacka-Ćwikła, M Mączyński, A Regiec - Cancers, 2021 - mdpi.com
Simple Summary Hematological malignancies are diseases involving the abnormal
production of blood cells. The aim of the study is to collect comprehensive information on …

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

NJ Bahlis, H Sutherland, D White… - Blood, The Journal …, 2018 - ashpublications.org
Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …